汇添富中证中药ETF联接(LOF)C(501012)利润分配表
| |
2025-12-31 |
2025-06-30 |
2024-12-31 |
2024-06-30 |
| 收入 |
-46,103,697.78 |
-39,141,849.00 |
-57,405,359.36 |
-142,570,539.14 |
| 利息合计 |
160,981.24 |
95,699.38 |
271,356.16 |
132,296.60 |
| 其中：存款利息收入 |
160,981.24 |
95,699.38 |
271,356.16 |
132,296.60 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-37,148,568.17 |
-24,172,133.24 |
-53,962,889.63 |
-19,107,726.06 |
| 其中：股票投资收益 |
100,734.15 |
-31,993.68 |
1,298,304.37 |
67,223.84 |
| 基金投资收益 |
-37,531,825.34 |
-24,209,693.26 |
-55,257,375.51 |
-19,181,290.66 |
| 债券投资收益 |
282,523.02 |
69,553.70 |
-3,638.89 |
6,540.36 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
- |
- |
-179.60 |
-199.60 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-10,141,084.79 |
-15,368,169.91 |
-4,985,276.01 |
-124,073,187.65 |
| 其他收入 |
1,024,973.94 |
302,754.77 |
1,271,450.12 |
478,077.97 |
| 费用 |
2,371,849.29 |
1,144,778.51 |
2,668,305.24 |
1,345,678.35 |
| 管理人报酬 |
444,065.13 |
218,976.00 |
504,963.01 |
251,378.53 |
| 基金托管费 |
59,208.65 |
29,196.77 |
67,328.37 |
33,517.12 |
| 销售服务费 |
1,680,067.88 |
802,899.88 |
1,906,734.50 |
961,852.13 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
188,507.63 |
93,705.86 |
189,279.36 |
98,930.57 |
| 利润总额 |
-48,475,547.07 |
-40,286,627.51 |
-60,073,664.60 |
-143,916,217.49 |
微信公众号
证券之星APP
基本资料
